Enovis Corp.

  • Market Cap: Small Cap
  • Industry: Industrial Manufacturing
  • ISIN: US1940145022
USD
27.96
-1.42 (-4.83%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

787.07 k

Shareholding (Mar 2025)

FII

9.81%

Held by 126 FIIs

DII

23.73%

Held by 75 DIIs

Promoter

0.00%

How big is Enovis Corp.?

22-Jun-2025

As of Jun 18, Enovis Corp. has a market capitalization of 1,763.96 million and reported net sales of 2,150.19 million with a net profit of -811.16 million over the latest four quarters. Shareholder's funds are 2,562.26 million, and total assets amount to 4,718.78 million.

As of Jun 18, Enovis Corp. has a market capitalization of 1,763.96 million, categorizing it as a Small Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 2,150.19 million, while the sum of net profit for the same period is -811.16 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at 2,562.26 million, and total assets amount to 4,718.78 million.

Read More

What does Enovis Corp. do?

22-Jun-2025

Enovis Corp. is a technology company specializing in orthopedic care and fabrication technology products, operating in the small-cap industrial manufacturing sector. As of March 2025, it reported net sales of $559 million and a net loss of $56 million, with a market cap of approximately $1.76 billion.

Overview:<BR>Enovis Corp. is a technology company that provides orthopedic care and fabrication technology products and services, operating in the Industrial Manufacturing industry within the small-cap market.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 559 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -56 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 1,763.96 Million (Small Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.52 <BR>Return on Equity: -2.24% <BR>Price to Book: 0.67<BR><BR>Contact Details:<BR>Address: 420 National Business Pkwy Fl 5, ANNAPOLIS JUNCTION MD: 20701-1079 <BR>Tel: 1 301 3239000 <BR>Fax: 1 301 3239001 <BR>Website: http://corporate.colfaxcorp.com/

Read More

Who are in the management team of Enovis Corp.?

22-Jun-2025

As of March 2022, the management team of Enovis Corp. includes Chairman Mitchell Rales, CEO Matthew Trerotola, and several independent directors: Patrick Allender, Thomas Gayner, Rhonda Jordan, Liam Kelly, and A. Clayton Perfall. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Enovis Corp. includes the following individuals:<BR><BR>- Mr. Mitchell Rales, Chairman of the Board<BR>- Mr. Matthew Trerotola, President, Chief Executive Officer, and Director<BR>- Mr. Patrick Allender, Presiding Independent Director<BR>- Mr. Thomas Gayner, Independent Director<BR>- Ms. Rhonda Jordan, Independent Director<BR>- Mr. Liam Kelly, Independent Director<BR>- Mr. A. Clayton Perfall, Independent Director<BR><BR>This team is responsible for overseeing the strategic direction and operations of the company.

Read More

Is Enovis Corp. overvalued or undervalued?

20-Sep-2025

As of May 4, 2023, Enovis Corp. is considered overvalued and risky, with poor financial metrics such as a Price to Book Value of 0.69, an EV to EBITDA ratio of 12.95, and negative returns on capital and equity, while underperforming the market with a year-to-date return of -24.41%.

As of 4 May 2023, the valuation grade for Enovis Corp. has moved from expensive to risky, indicating a shift towards a more cautious outlook. The company appears to be overvalued given its current financial metrics, particularly with a Price to Book Value of 0.69 and an EV to EBITDA ratio of 12.95, which suggests that investors are paying a premium relative to the company's earnings before interest, taxes, depreciation, and amortization. Additionally, the negative ROCE of -0.92% and ROE of -2.24% further highlight the company's struggles in generating returns for shareholders.<BR><BR>When compared to peers, Enovis Corp. has a significantly lower EV to EBITDA ratio than Zurn Elkay Water Solutions Corp. at 22.5876 and Watts Water Technologies, Inc. at 19.0673, both of which are performing better in terms of valuation. The stock's performance has been underwhelming, with a year-to-date return of -24.41%, contrasting sharply with the S&P 500's return of 12.22% during the same period, reinforcing the notion that Enovis Corp. is not only overvalued but also struggling relative to broader market trends.

Read More

Is Enovis Corp. technically bullish or bearish?

14-Oct-2025

As of October 10, 2025, Enovis Corp. is in a bearish trend with weak strength, indicated by negative signals from daily moving averages and Bollinger Bands, despite some mildly bullish signals from the weekly MACD and KST, and has underperformed the S&P 500 with a year-to-date return of -32.25%.

As of 10 October 2025, the technical trend for Enovis Corp. has changed from mildly bearish to bearish. The current stance is bearish with weak strength indicated by the daily moving averages and the bearish signals from both the Bollinger Bands and the monthly MACD. The weekly MACD and KST show mildly bullish signals, but these are overshadowed by the overall bearish trend. The stock has significantly underperformed against the S&P 500 across multiple periods, with a year-to-date return of -32.25% compared to the S&P 500's 11.41%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Poor Management Efficiency with a low ROCE of 1.97%

  • The company has been able to generate a Return on Capital Employed (avg) of 1.97% signifying low profitability per unit of total capital (equity and debt)
2

The company has declared Negative results for the last 5 consecutive quarters

3

Risky -

4

Consistent Underperformance against the benchmark over the last 3 years

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Industrial Manufacturing

stock-summary
Market cap

USD 1,795 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.53

stock-summary
Return on Equity

-3.40%

stock-summary
Price to Book

0.70

Revenue and Profits:
Net Sales:
565 Million
(Quarterly Results - Jun 2025)
Net Profit:
-36 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-8.81%
0%
-8.81%
6 Months
-8.87%
0%
-8.87%
1 Year
-42.97%
0%
-42.97%
2 Years
-45.14%
0%
-45.14%
3 Years
-51.31%
0%
-51.31%
4 Years
-63.79%
0%
-63.79%
5 Years
-56.24%
0%
-56.24%

Enovis Corp. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-7.14%
EBIT Growth (5y)
-160.90%
EBIT to Interest (avg)
1.10
Debt to EBITDA (avg)
3.70
Net Debt to Equity (avg)
0.52
Sales to Capital Employed (avg)
0.46
Tax Ratio
1.26%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
1.97%
ROE (avg)
1.31%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.69
EV to EBIT
-86.68
EV to EBITDA
12.95
EV to Capital Employed
0.80
EV to Sales
1.48
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-0.92%
ROE (Latest)
-2.24%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 95 Schemes (66.44%)

Foreign Institutions

Held by 126 Foreign Institutions (9.81%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 1.02% vs -0.39% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 34.35% vs 92.10% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "564.50",
          "val2": "558.80",
          "chgp": "1.02%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "69.10",
          "val2": "40.60",
          "chgp": "70.20%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "21.30",
          "val2": "21.40",
          "chgp": "-0.47%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-16.20",
          "val2": "-17.70",
          "chgp": "8.47%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-36.50",
          "val2": "-55.60",
          "chgp": "34.35%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-4.30%",
          "val2": "-55.10%",
          "chgp": "5.08%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 23.45% vs 9.22% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -1,437.92% vs -40.84% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,107.60",
          "val2": "1,707.20",
          "chgp": "23.45%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "281.20",
          "val2": "187.80",
          "chgp": "49.73%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "57.70",
          "val2": "19.90",
          "chgp": "189.95%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-768.50",
          "val2": "-41.30",
          "chgp": "-1,760.77%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-827.40",
          "val2": "-53.80",
          "chgp": "-1,437.92%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1.80%",
          "val2": "-17.20%",
          "chgp": "1.54%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
564.50
558.80
1.02%
Operating Profit (PBDIT) excl Other Income
69.10
40.60
70.20%
Interest
21.30
21.40
-0.47%
Exceptional Items
-16.20
-17.70
8.47%
Consolidate Net Profit
-36.50
-55.60
34.35%
Operating Profit Margin (Excl OI)
-4.30%
-55.10%
5.08%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 1.02% vs -0.39% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 34.35% vs 92.10% in Mar 2025

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
2,107.60
1,707.20
23.45%
Operating Profit (PBDIT) excl Other Income
281.20
187.80
49.73%
Interest
57.70
19.90
189.95%
Exceptional Items
-768.50
-41.30
-1,760.77%
Consolidate Net Profit
-827.40
-53.80
-1,437.92%
Operating Profit Margin (Excl OI)
-1.80%
-17.20%
1.54%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 23.45% vs 9.22% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -1,437.92% vs -40.84% in Dec 2023

stock-summaryCompany CV
About Enovis Corp. stock-summary
stock-summary
Enovis Corp.
Industrial Manufacturing
Colfax Corporation is a technology company. The Company provides orthopedic care and fabrication technology products and services. It operates through two segments: Fabrication Technology and Medical Technology. Fabrication Technology segment is a supplier of welding equipment, cutting equipment, automated welding and cutting systems, and consumables. Medical Technology segment is a provider of orthopedic solutions, providing orthopedic devices, software and services. Its fabrication technology products are marketed under the ESAB brand. ESAB's range of cutting and welding consumables includes electrodes, cored and solid wire and fluxes. The Company, through its subsidiary DJO Global, Inc. (DJO), provides medical devices that provide solutions for musculoskeletal health, vascular health and pain management. It offers products under various brands, including Aircast, Chattanooga, Regeneration, COMPEX, DJO Surgical, DONJOY, DR.COMFORT, PROCARE, Bell-Horn, Exos, Fast Freeze and Saunders.
Company Coordinates stock-summary
Company Details
420 National Business Pkwy Fl 5 , ANNAPOLIS JUNCTION MD : 20701-1079
Registrar Details